Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 290M | 25.4% |
| Gross Profit | 182M | 31.4% |
| Cost of Revenue | 108M | 16.5% |
| Operating expense | 77M | 4% |
| Net Income | 137M | 46.9% |
| EBITDA | 185M | 37.2% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 2.12B | 7.5% |
| Total Liabilities | 1.67B | 0.9% |
| Total Equity | 453M | 56.4% |
| Shares Outstanding | 127M | 0.5% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | 115M | 106.8% |
| Cash from investing | -167M | 298.4% |
| Cash from financing | 19M | 95.7% |
EPS
Financial Highlights for Halozyme Therapeutics in Q3 '24
Halozyme Therapeutics reported a revenue of 290M, which is a 25.4% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 182M, marking a 31.4% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 108M, a 16.5% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 77M, showing a 4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 137M, showing a 46.9% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 185M, showing a 37.2% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Halozyme Therapeutics with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
